Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

Penel, N; Le Cesne, A; Bui, B N; Perol, D; Brain, E G; Ray-Coquard, I; Guillemet, C; Chevreau, C; Cupissol, D; Chabaud, S; Jimenez, M; Duffaud, F; Piperno-Neumann, S; Mignot, L; Blay, J-Y

Penel, N; Le Cesne, A; Bui, B N; Perol, D; Brain, E G; Ray-Coquard, I; Guillemet, C; Chevreau, C; Cupissol, D; Chabaud, S; Jimenez, M; Duffaud, F; Piperno-Neumann, S; Mignot, L; Blay, J-Y.

Affiliation

Penel N; Department of General Cancerology, Oscar Lambret Center, Lille, France. n-penel@o-lambret.fr

Ann Oncol ; 22(2): 452-7, 2011 Feb.

Article in En | MEDLINE | ID: mdl-20622000

Subject(s)

Antineoplastic Agents/therapeutic use; Fibroma/drug therapy; Piperazines/therapeutic use; Pyrimidines/therapeutic use; Adult; Aged; Antineoplastic Agents/adverse effects; Benzamides; Disease Progression; Follow-Up Studies; Humans; Imatinib Mesylate; Middle Aged; Piperazines/adverse effects; Pyrimidines/adverse effects; Recurrence; Survival Analysis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Fibroma / Antineoplastic Agents Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: France Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google